Logo

Opaldia to Distribute Agendia s MammaPrint and CupPrint Tests in UK

Mar 30, 2006

NEW YORK, March 30 (GenomeWeb News) - Opaldia will distribute Agendia's MammaPrint and CupPrint tests in the United Kingdom, the companies said today.

 

MammaPrint uses a 70-gene profile to classify breast cancer patients as 'low' or 'high' risk for developing distant metastasis in a 10-year period.

 

The CupPrint test, meantime, is intended to identify the primary tumor in patients with cancer of unknown primary.

 

Financial terms of the agreement were not disclosed.

Breaking News
The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.